Drug Trial Radar · NCT04292119
Lorlatinib Combinations in Lung Cancer
Last checked: Nov 19, 2026Latest source record: Mar 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
96
Planned (sponsor's estimate)
Start
May 1, 2020
Primary completion
Dec 1, 2022
Study completion Mar 1, 2023
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Array BioPharma; Pfizer
- First posted
- Mar 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. * This research study involves four study drugs. * Lorlatinib * Binimetinib * Crizotinib * TNO155
Conditions
- Lung Cancer
- Anaplastic Lymphoma Kinase Gene Translocation
- ROS1 Rearrangement
- Relapsed Cancer
- MET Amplification
- Resistant Cancer
- NSCLC
Interventions
LorlatinibDrug
Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155. Crizotinib taken orally twice daily for 28 days.
CrizotinibDrug
Crizotinib will be taken orally twice daily for 28 days. Binimetnib taken orally twice daily for 28 days.
BinimetinibDrug
Binimetinib will be taken orally twice daily for 28 days.
TNO155Drug
TNO155 will be taken orally once daily for 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose as assessed by CTCAE v5.0. Phase I.Time frame: 28 days (binimetinib and crizotinib arm), 21 days (TNO155 arm)
- The objective response rate, including partial and complete responses, as evaluated by RECIST v1.1. Phase IITime frame: 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital Cancer Center
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.